ClinicalTrials.gg
CompletedNCT01101061Updated Jul 31, 2019Results posted

A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women

A Phase 1 interventional study of Romosozumab and Placebo in Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing romosozumab in Bone Diseases, Metabolic — none open to participants now, 1 under way, none of them phase 3. romosozumab · Bone Diseases, Metabolic.

Enrollment
9th of 11
31 · median 74
Started
2010
the only one that year
Phase 1
4 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
9 of 11
Amgen

Among the 11 studies testing romosozumab in Bone Diseases, Metabolic, this one is the 9th largest by enrollment, is the only one that started in 2010, is one of 4 in phase 1, and was the 4th registered.

Bone Diseases, Metabolic

662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

None of the 11 studies testing romosozumab in Bone Diseases, Metabolic is open now. The open studies under Bone Diseases, Metabolic, anywhere →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 45 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing romosozumab in Bone Diseases, Metabolic as a file.
02

Study summary

The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese and non-Japanese women.

03

Conditions studied

  • Osteopenia

Keywords

  • Amgen
  • Phase 1
  • Postmenopausal
  • Japanese
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects must be first (4 grandparents, biologic parents and subject born in Japan), second (4 grandparents and biological parents born in Japan) or third (4 grandparents born in Japan) generation Japanese
  • ≤ 25 kg/m², inclusive at screening
  • females defined as 12 continuous months of spontaneous amenorrhea confirmed by a serum follicle-stimulating hormone (FSH) result > 40 mIU/mL, or 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy) as documented in medical history (verified with an operative note, if available)

Exclusion criteria

Exclusion Criteria:

  • Osteoporosis, as defined by bone mineral density (BMD) T-scores of the lumbar spine (L1-L4) or total evaluable vertebrae (if fewer than L1-L4); or femoral neck ≤ -2.5
  • History of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis;
  • Diagnosed with any condition that will affect bone metabolism
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Romosozumab

    Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.

    Drug: Romosozumab

  • Placebo comparator
    Placebo

    Participants will receive a single dose of placebo.

    Drug: Placebo

Interventions

  • Administered by subcutaneous injection

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.

    Time frame: Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments.

  2. Number of Participants Who Developed Anti-romosozumab Binding Antibodies

    Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.

    Time frame: Day 29, and end of study (day 57 for participants assigned to 1 or 3 mg/kg romosozumab/placebo or day 85 for participants assigned to 5 mg/kg romosozumab/placebo)

  3. Serum Calcium Levels

    Time frame: Baseline, days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85

  4. Serum Intact Parathyroid Hormone (iPTH) Levels

    Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85

Secondary outcomes

  1. Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)

    Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85

  2. Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)

    Time frame: Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85

  3. Percent Change From Baseline in Sclerostin

    Time frame: Baseline and days 12, 29, 43, 57, 71, and 85

  4. Time to Maximum Observed Concentration of Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  5. Maximum Observed Concentration of Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  6. Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  7. Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  8. Apparent Clearance (CL/F) of Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  9. Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

  10. Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab

    Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

    Time frame: Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.

07

Results

Posted Jul 31, 2019

Participant flow

This study was conducted at 2 study centers in the United States. Eligible participants were healthy, postmenopausal first, second, or third generation Japanese women and non-Japanese women residing in the United States.

Participant flow — Overall Study
MilestoneJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Started667624
Received study drug666624
Completed666624
Not completed001000
Withdrew: Adverse event001000

Outcome measures

PrimaryNumber of Participants With Adverse Events

A serious adverse event (SAE) is defined as an adverse event that * is fatal * is life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other significant medical hazard. A treatment-related AE is any treatment-emergent AE that per investigator review has a reasonable possibility of being caused by the investigational product.

Time frame:
Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Any adverse event643624
Serious adverse events000000
Treatment-related adverse events212100
AEs leading to discontinuation of study drug000000
Deaths000000
PrimaryNumber of Participants Who Developed Anti-romosozumab Binding Antibodies

Participants who were negative for anti-romosozumab binding antibodies at baseline with a positive result at any time post-baseline.

Time frame:
Day 29, and end of study (day 57 for participants assigned to 1 or 3 mg/kg romosozumab/placebo or day 85 for participants assigned to 5 mg/kg romosozumab/placebo)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-romosozumab Binding Antibodies
ParticipantsJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Number of Participants Who Developed Anti-romosozumab Binding Antibodies000000
PrimarySerum Calcium Levels
Time frame:
Baseline, days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Reported as:
Mean · mmol/L
Serum Calcium Levels
mmol/LJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Baseline2.34 ± 0.042.31 ± 0.042.33 ± 0.032.38 ± 0.032.28 ± 0.082.45 ± 0.04
Day 22.33 ± 0.042.34 ± 0.032.31 ± 0.032.36 ± 0.032.34 ± 0.042.40 ± 0.05
Day 32.33 ± 0.052.36 ± 0.042.31 ± 0.032.38 ± 0.032.34 ± 0.012.43 ± 0.03
Day 42.32 ± 0.052.31 ± 0.032.30 ± 0.032.32 ± 0.032.38 ± 0.022.36 ± 0.04
Day 62.39 ± 0.052.30 ± 0.032.31 ± 0.042.35 ± 0.042.28 ± 0.022.40 ± 0.03
Day 82.39 ± 0.052.25 ± 0.022.31 ± 0.032.29 ± 0.032.35 ± 0.002.38 ± 0.03
Day 122.35 ± 0.062.27 ± 0.052.33 ± 0.032.28 ± 0.022.33 ± 0.032.28 ± 0.04
Day 222.31 ± 0.032.31 ± 0.032.28 ± 0.052.25 ± 0.032.33 ± 0.002.36 ± 0.03
Day 292.37 ± 0.032.30 ± 0.042.28 ± 0.032.30 ± 0.022.36 ± 0.042.38 ± 0.05
Day 432.35 ± 0.042.33 ± 0.032.28 ± 0.032.34 ± 0.042.30 ± 0.072.34 ± 0.01
Day 572.37 ± 0.032.32 ± 0.042.29 ± 0.042.30 ± 0.032.28 ± 0.002.31 ± 0.02
Day 712.34 ± 0.01——2.39 ± 0.02——
Day 852.29 ± 0.01——2.35 ± 0.02——
PrimarySerum Intact Parathyroid Hormone (iPTH) Levels
Time frame:
Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Reported as:
Mean · pmol/L
Serum Intact Parathyroid Hormone (iPTH) Levels
pmol/LJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Baseline4.47 ± 0.974.24 ± 0.704.93 ± 0.843.63 ± 0.623.77 ± 1.652.73 ± 0.37
Day 24.51 ± 0.784.92 ± 0.785.01 ± 0.474.23 ± 0.543.50 ± 1.492.57 ± 0.23
Day 34.93 ± 0.714.69 ± 0.695.38 ± 0.444.58 ± 0.763.50 ± 1.062.89 ± 0.37
Day 44.47 ± 0.845.09 ± 0.695.09 ± 0.235.20 ± 1.133.93 ± 1.703.55 ± 0.73
Day 64.21 ± 0.674.97 ± 0.935.75 ± 0.724.44 ± 0.773.82 ± 1.493.66 ± 0.66
Day 84.19 ± 0.955.91 ± 0.865.23 ± 0.684.79 ± 0.904.14 ± 1.913.98 ± 0.68
Day 125.04 ± 0.956.42 ± 0.595.46 ± 0.415.80 ± 0.614.19 ± 1.864.46 ± 0.64
Day 224.69 ± 0.745.57 ± 0.646.15 ± 0.567.09 ± 0.845.46 ± 2.714.62 ± 0.68
Day 294.83 ± 0.995.02 ± 0.745.92 ± 0.686.14 ± 0.724.83 ± 2.814.43 ± 0.40
Day 434.61 ± 0.896.03 ± 0.735.27 ± 0.325.61 ± 0.843.93 ± 1.273.53 ± 0.35
Day 573.89 ± 0.844.90 ± 0.644.87 ± 0.394.86 ± 0.552.76 ± 0.852.68 ± 0.27
Day 713.40 ± 0.85——4.10 ± 0.47——
Day 853.02 ± 0.80——3.82 ± 0.58——
SecondaryMaximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame:
Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Reported as:
Mean · percent change
Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
percent changeJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)26.85 ± 6.3959.23 ± 12.21102.57 ± 18.26196.37 ± 29.798.30 ± 1.78164.44 ± 35.58
SecondaryMaximum Percent Change From Baseline in Serum C-telopeptide (CTX)
Time frame:
Baseline and days 2, 3, 4, 6, 8, 12, 22, 29, 43, 57, 71, and 85
Reported as:
Mean · percent change
Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)
percent changeJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)-12.64 ± 1.40-16.19 ± 7.36-35.92 ± 1.94-39.17 ± 5.13-25.46 ± 8.52-43.32 ± 9.96
SecondaryPercent Change From Baseline in Sclerostin
Time frame:
Baseline and days 12, 29, 43, 57, 71, and 85
Reported as:
Mean · percent change
Percent Change From Baseline in Sclerostin
percent changeJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Day 12-3.78 ± 3.726639.01 ± 534.5013749.61 ± 1091.6317028.81 ± 1875.81-17.95 ± 6.3814652.96 ± 1349.38
Day 29591.80 ± 596.471602.70 ± 231.777667.80 ± 675.4512723.54 ± 2138.65-14.54 ± 1.789581.13 ± 1283.73
Day 43-15.43 ± 11.39467.07 ± 55.623384.02 ± 613.996844.74 ± 1730.04-9.35 ± 4.594487.33 ± 1771.30
Day 57-17.89 ± 11.96167.37 ± 28.33911.23 ± 156.092836.61 ± 1109.97-0.41 ± 12.651826.83 ± 917.98
Day 71-39.80 ± 3.87——997.02 ± 532.06——
Day 85-27.41 ± 2.02——415.38 ± 243.40——
SecondaryTime to Maximum Observed Concentration of Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Median · days
Time to Maximum Observed Concentration of Romosozumab
daysJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Time to Maximum Observed Concentration of Romosozumab5.0 (5.0 to 8.0)5.0 (3.0 to 12)5.0 (5.0 to 7.0)5.0 (5.0 to 7.0)
SecondaryMaximum Observed Concentration of Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · µg/mL
Maximum Observed Concentration of Romosozumab
µg/mLJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Maximum Observed Concentration of Romosozumab4.06 ± 1.4517.1 ± 4.733.8 ± 8.118.6 ± 1.1
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · µg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab
µg*day/mLJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab64.0 ± 27.0344 ± 90804 ± 320412 ± 136
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · µg*day/mL
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab
µg*day/mLJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab64.7 ± 26.8347 ± 90806 ± 323421 ± 147
SecondaryApparent Clearance (CL/F) of Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · mL/day/kg
Apparent Clearance (CL/F) of Romosozumab
mL/day/kgJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Apparent Clearance (CL/F) of Romosozumab18.6 ± 10.09.27 ± 2.646.98 ± 2.357.91 ± 2.68
SecondaryHalf-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · days
Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab
daysJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab—15.1 ± NA16.2 ± 4.115.3 ± 6.2
SecondaryHalf-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab

Serum concentrations of romosozumab were measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 ng/mL.

Time frame:
Predose, 12 hours postdose, and on days 2, 3, 4, 6, 8, 12, 22, 29, 43, and 57, and days 71 and 85 for participants assigned tp 5 mg/kg romosozumab/placebo.
Reported as:
Mean · days
Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab
daysJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: Romosozumab 3 mg/kg
Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab5.82 ± 1.056.31 ± 1.147.19 ± 1.556.81 ± 2.69

Adverse events

Collected over Participants who received a 1 or 3 mg/kg dose (romosozumab or placebo) were followed for 2 months (day 57) after study drug administration and participants who received 5 mg/kg were followed for 3 months (day 85) for safety assessments. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Japanese Women: Placebo0/6 (0%)0/6 (0%)6/6 (100%)
Japanese Women: Romosozumab 1 mg/kg0/6 (0%)0/6 (0%)4/6 (66.7%)
Japanese Women: Romosozumab 3 mg/kg0/6 (0%)0/6 (0%)3/6 (50%)
Japanese Women: Romosozumab 5 mg/kg0/6 (0%)0/6 (0%)6/6 (100%)
Non-Japanese Women: Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Non-Japanese Women: Romosozumab 3 mg/kg0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventJapanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kg
Vessel puncture site haematomaGeneral disorders2/61/61/61/61/20/4
Upper respiratory tract infectionInfections and infestations1/60/60/60/61/20/4
Venomous stingInjury, poisoning and procedural complications0/60/60/60/61/20/4
HeadacheNervous system disorders1/62/61/63/60/21/4
Vaginal haemorrhageReproductive system and breast disorders0/60/60/60/61/20/4
Injection site haematomaGeneral disorders0/60/62/61/60/20/4
Abdominal pain upperGastrointestinal disorders0/60/60/60/60/21/4
ConstipationGastrointestinal disorders0/60/60/60/60/21/4
FatigueGeneral disorders0/60/60/60/60/21/4
Transaminases increasedInvestigations0/60/60/60/60/21/4

Baseline characteristics

All treated participants

Age, Categorical
Age, Categorical(Participants)Japanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kgTotal
<=18 years0000000
Between 18 and 65 years45632424
>=65 years2103006
Age, Continuous
Age, Continuous(years)Japanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kgTotal
Mean60.8 ± 5.759.3 ± 4.961.7 ± 3.059.7 ± 7.757.5 ± 3.555.0 ± 4.859.5 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Japanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kgTotal
Female66662430
Male0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Japanese Women: PlaceboJapanese Women: Romosozumab 1 mg/kgJapanese Women: Romosozumab 3 mg/kgJapanese Women: Romosozumab 5 mg/kgNon-Japanese Women: PlaceboNon-Japanese Women: Romosozumab 3 mg/kgTotal
Asian66661025
White0000145
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Nov 2010, 5 months.

Results were first posted in Jul 2019, 8 years 8 months after primary completion.

Of 13 phase 1 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 37. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2010
First posted
Apr 9, 2010
StartActual
May 3, 2010
Primary completionActual
Nov 1, 2010
CompletionActual
Nov 1, 2010
Results first posted
Jul 31, 2019
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01101061
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
May 3, 2010
Primary completion
Nov 1, 2010
Completion
Nov 1, 2010
Results posted
Jul 31, 2019
Last update
Jul 31, 2019

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion